Archive for March, 2011

Green Light for Yervoy May Slow Melanoma in Its Tracks

Monday, March 28th, 2011

As we wrote about back in June, the most promising drug in the war on Melanoma, ipilimumab, was fast-tracked and finally approved as “Yervoy” for Bristol-Myers Squibb by the FDA last week.

Ipi is an immune therapy drug: it tries to activate or stimulate the immune system to clear cancer cells. While ipi’s funny name has not improved much with a brand name like Yervoy, it is anything but laughable.  We have been challenged to make ANY progress with drug therapy and this new therapy is a welcome advance. With the usual current immuno-therapy treatments, such as interleukin, we haven’t been able to significantly extend the immune response to melanoma cells.  As described on WebMD:

Yervoy appears to extend survival when used as a first-line treatment for inoperable stage III or stage IV melanoma, Bristol-Myers announced earlier this week. Details of the study will be reported at the June meeting of the American Society of Clinical Oncology.

Yervoy is a biologic therapy. It’s a kind of man-made antibody (a monoclonal antibody) that blocks a crucial switch on immune cells called CTLA-4. Cancers use this switch to turn off the body’s anticancer immune responses.

Most drugs like this come with possibly severe side effects, and Yervoy is no exception. The drug can provoke powerful autoimmune reactions in which the immune system attacks normal cells in the body. In clinical trials, nearly 13% of patients taking Yervoy had severe or fatal autoimmune reactions.

Even with those caveats this does seem to be some light at the end of the tunnel:

FDA approved the drug based on a Bristol Myers study of 676 people with advanced, inoperable melanoma who had already failed two other treatments, giving them a very short life expectancy. They were given one of three treatments: ipilimumab by itself, ipilimumab combined with another immune-stimulating treatment, or the immune-stimulating treatment alone.

Average survival was 10 months with ipilimumab versus just more than six months for the others. But a very small group of patients survived longer than six years, suggesting that with more study the drug could be targeted to those who will respond the most.

About 85 percent of patients had little response to the drug. Researchers say the response rate should improve as the drug is used earlier in the disease cycle.

“I think the direction this is headed is toward intervening earlier, when patients’ immune systems are still intact, rather than waiting until they are so sick,” said Dr. Anna Pavlick, director of the New York University’s melanoma program. Pavlick, a spokeswoman for the Skin Cancer Foundation, helped conduct several early-stage trials of ipilimumab.

Bristol-Myers Squibb expects to begin shipping YERVOY within weeks.

Share

Another Season, Another Reason…

Monday, March 21st, 2011

No, the end of our title line, “Another Season, Another Reason…” is NOT “for makin’ whoopie” as the song goes.  It’s a reminder that Spring has sprung whether or not you feel the new season in the air in your neck of the woods yet.  That means our hours of sunshine are increasing…and THAT is another reason to remember to make your annual appointment for a comprehensive skin cancer skin exam — we hope at MoleSafe.  However, if you’re not in our neck of the woods with our six locations, there’s another resource that may be coming to YOU soon:

Thanks to our friends at the Skin Cancer Foundation, you can take advantage of their 4th annual skin cancer screening tour, which kicked off again just last week.

The 2011 Tour will make an estimated 80 stops in 24 states. After kicking off in Jacksonville, Florida on March 11, the Tour bus, a 38-foot customized RV with two exam rooms, will travel around the country stopping in some new cities this year. The Tour reaches New York City just in time for Skin Cancer Awareness Month in May. The 2011 Road to Healthy Skin Tour will conclude in New Orleans on September 17.

Tour Route: Skin Cancer Foundation Screening Bus

Tour Route: Skin Cancer Foundation Screening Bus

So, here, there and everywhere (a line from another great song!) is an opportunity to look out for yourself and your loved ones; no excuses! Plan your checkup today.  You can even use their site to “tell a friend.” Please do; a life could depend on it.

Share

Let’s Meet in May…

Friday, March 18th, 2011

Just a head’s up that I’ll be speaking in Freehold, NJ, at our CentraState location of MoleSafe on May 2, 2011 at 6:30P.  More details to come, but please come by if you are in the area.  Of course, questions about MoleSafe are always welcome.  Just reach out to any of our 6 locations and please remember to book your annual screening soon!

Share

A Winner On and Off the Course

Monday, March 7th, 2011

Rory Sabbatini won another golf tournament last week, making it a sixth PGA title and earning him a slot in the Masters. But he won a bigger round just a few months ago, when he caught and had a skin cancer on his face removed.

Rory Sabbatini Prevails on the Course and Against Skin Cancer

Rory Sabbatini Prevails on the Course and Against Skin Cancer

As reported by Reuters, “Nine days after the birth of the Sabbatinis’ third child, Bodhi Mac, the golfer went under the knife to have a cancerous growth removed from his face. The scare has led to him wearing a broad rimmed hat and smearing his face in a special sun-cream each time he steps on a golf course.”

I think Rory deserves the Hats On Award, not just for making sun protection a fashion statement on the course, but for all he’s doing to promote awareness.  As posted in Golf Week,

The bad news is five-time PGA Tour winner Rory Sabbatini was diagnosed with skin cancer in December. The good news is he is “fine” after surgery, though he will have to be careful and wear big hats and be diligent in applying sunscreen.  The better news is Sabbatini, among the top 20 in Tour earnings four of the past seven years, is planning to raise money for charity through a sunscreen-related launch at next week’s PGA Merchandise Show.

SmartShield has announced a partnership with Rory promoting it as his official sunscreen. Rory began wearing the SmartShield logo on his shirt and covering his face and arms with the sunscreen at the Sony Open in Hawaii. rory Sabbatini with sunscreenAs golf season is dawning again with Spring around the corner, make sure you are course-correcting with these suggestions from another terrific post in Golf Week :

“Everybody needs to be smart,” said David Donatucci, the PGA’s director of fitness and performance. “As a golfer, you’re out in the sun for five hours. You need sunscreen. You need to reapply sunscreen. You need to drink water. You need to eat a little something. All these things need to become habits, and that’s the message we are spreading….Sunscreens are becoming more user-friendly.

Golfers should wear it every time they play, regardless of conditions. Playing golf in cloudy conditions doesn’t protect you from UV rays. They come through the clouds.”

Share

Melanoma screening and detection news

Tuesday, March 1st, 2011

Duke University is testing a promising new Melanoma detection laser - which, for the first time, gives scientists the ability to identify substantial chemical differences between cancerous and healthy skin tissues and prevent unnecessary biopsies, by identifying a pigment more prominent in cancerous moles. As of now it is being tested on biopsied tissue samples, but may eventually be an effective pre-biopsy tool as well.

There are two issues at play here.  The first is the need for improved detection of Melanoma.  As we’ve noted here repeatedly, the MoleSafe technique takes skin cancer  assessments and screenings to the next level, well beyond the “naked eye exam,” which, as I described again in my last post, is a good precursory practice between more rigorous screenings but is out-dated when used as the exclusive approach.  The second issue is that there is still the challenge in interpreting the results of biopsies of suspicious moles, no matter how they are discovered.

As the Duke article says,

Doctors typically use a light and a magnifying glass or tissue biopsy, where a pathologist removes suspicious skin cells and looks at them under a microscope, to spot signs of disease. But using a lens and a light is a “17th century” technique that is only 85 percent accurate, at best, and tissue biopsy is not much more reliable…

In 14 percent of biopsy diagnoses, pathologists would disagree on whether or not the sampled cells were cancerous, according to a 2010 study published in the Journal of American Academy of Dermatology. The statistic implies that two pathologists would have opposing diagnoses on 214,000 to 643,000 melanoma cases each year.

Since, as a result, many doctors will follow the “when in doubt, cut it out” philosophy, this new laser holds the promise of maximizing accurate diagnoses, and down the road perhaps being a promising pre-biopsy screening tool as well.

———-

In other screening news, Bloomberg’s BusinessWeek reported on a story posted in the Archives of Dermatology on the increased skin self-exams conducted by kidney transplant patients from good old-fashioned education and information. Compliance in self-exams jumped to 89% among those in the study group, resulting in a dozen patients actually spotting an area of concern and making an appointment with their dermatologist.

The patients in the intervention group were given printed educational materials to promote skin self-examination. The patients in the control group did not receive the educational materials. Follow-up revealed that patients in the intervention group were much more likely to perform skin self-examinations than those in the control group — 89 percent vs. 22 percent.

This just underscores the ongoing need for education and awareness.  We hope more physicians will take the time to educate ALL patients – high risk or not.

Share